AMOYTOP(SH:688278) Shang Hai Zheng Quan Bao·2025-08-20 20:55Core Viewpoint - The company has released its 2025 semi-annual report, which reflects its financial status and operational performance, ensuring compliance with relevant regulations and internal procedures [8][9]. Group 1: Company Overview - The company is identified as Xiamen Te Bao Biological Engineering Co., Ltd., with stock code 688278 [12]. - The semi-annual report is unaudited and emphasizes the importance of reading the full report for a comprehensive understanding of the company's performance [4][1]. Group 2: Financial Data - The total amount raised from the initial public offering was RMB 383.16 million, with a net amount of RMB 330.45 million after deducting issuance costs [13]. - As of June 30, 2025, the company has utilized RMB 0.304 million in the current year and a cumulative total of RMB 385.13 million from the raised funds [15]. Group 3: Fund Management - The company has established a fundraising management system to ensure the proper use and management of raised funds, adhering to legal and regulatory requirements [16]. - A tripartite supervision agreement was signed with the sponsor and the bank for the storage of raised funds, ensuring compliance with the agreement [17]. Group 4: Fund Usage and Adjustments - The company has not used idle raised funds for temporary working capital or cash management during the reporting period [20][21]. - There was an adjustment in the investment amounts for specific projects, with the protein drug production project receiving an increase from RMB 159.40 million to RMB 199.40 million [26].